Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Ngm biopharmaceuticals s return on capital employed overview - What They Never Told You

According to Benzinga Pro data, during Q4, NGM Biopharmaceuticals (NASDAQ:NGM) posted sales of $20.96 million. Earnings were up 5.65%, but NGM Biopharmaceuticals still reported an overall loss of $27.23 million. NGM Biopharmaceuticals collected $18.57 million in revenue during Q3, but reported earnings showed a $28.86 million loss.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.